Publication Details

Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine.

Rai KR, Freter CE, Mercier RJ, Cooper MR, Mitchell BS, Stadtmauer EA, Santábarbara P, Wacker B, Brettman L. J Clin Oncol. 2002; 20 (18): 3891-7

This phase II pilot study determined the efficacy and safety of alemtuzumab (Campath-1H; Burroughs Wellcome, United Kingdom) in patients with chronic lymphocytic leukemia (CLL), all of whom had previously received fludarabine and other chemotherapy regimens.

PubMedID: 12228210